Greater Cannabis Company, Inc. (GCAN) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
15 WALKER AVE, BALTIMORE, MD 21208 |
| State of Incorp. | FL |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 57 | 167 | 270 | 378 | 113 | 25 | |||
| Cash and cash equivalent | 57 | 167 | 270 | 378 | 113 | 25 | |||
| Receivables | 28 | ||||||||
| Prepaid expense | 10 | ||||||||
| Other undisclosed current assets | 37 | ||||||||
| Total current assets: | 57 | 167 | 270 | 378 | 160 | 53 | |||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill), including: | 0 | 5 | 10 | 15 | 20 | (100) | |||
| Intangible assets, net (excluding goodwill) | (10) | (5) | (100) | ||||||
| Other undisclosed intangible assets, net (including goodwill) | 0 | 5 | 10 | 25 | 25 | ||||
| Other undisclosed noncurrent assets | 100 | ||||||||
| Total noncurrent assets: | 0 | 5 | 10 | 15 | 20 | ||||
| TOTAL ASSETS: | 58 | 172 | 280 | 393 | 180 | 53 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 467 | 402 | 322 | 233 | 160 | 186 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 18 | 1 | 21 | ||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 203 | 152 | 98 | ||
| Accounts payable | 8 | 6 | 16 | 12 | 7 | 18 | |||
| Accrued liabilities | 459 | 396 | 306 | 50 | |||||
| Debt | 431 | 431 | 243 | 369 | 23 | ||||
| Derivative instruments and hedges, liabilities | 17 | 726 | |||||||
| Due to related parties | ✕ | ✕ | ✕ | 260 | 260 | 260 | 260 | ||
| Other undisclosed current liabilities | 427 | ||||||||
| Total current liabilities: | 898 | 834 | 825 | 862 | 460 | 1,599 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 898 | 834 | 825 | 862 | 460 | 1,599 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (840) | (661) | (545) | (469) | (280) | (1,547) | |||
| Preferred stock | |||||||||
| Common stock | 805 | 805 | 733 | 509 | 465 | 39 | |||
| Additional paid in capital | 3,006 | 3,006 | 3,006 | 2,946 | 2,576 | 784 | |||
| Accumulated deficit | (4,660) | (4,481) | (4,293) | (3,933) | (3,330) | (2,379) | |||
| Other undisclosed equity, attributable to parent | 9 | 9 | 9 | 9 | 9 | 9 | |||
| Total equity: | (840) | (661) | (545) | (469) | (280) | (1,547) | |||
| TOTAL LIABILITIES AND EQUITY: | 58 | 172 | 280 | 393 | 180 | 53 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 13 | 48 | 7 | |||||
| Revenue from related parties | ✕ | ✕ | ✕ | 3 | ||||
| Cost of revenue (Cost of Product and Service Sold) | (13) | (48) | (3) | |||||
| Gross profit: | (0) | (0) | 4 | |||||
| Operating expenses | (156) | (175) | (177) | (343) | (294) | (532) | ||
| Other undisclosed operating income | 3 | |||||||
| Operating loss: | (156) | (175) | (177) | (343) | (294) | (525) | ||
| Nonoperating expense | (23) | (13) | (183) | (259) | (657) | (1,123) | ||
| Interest and debt expense | (13) | (61) | (18) | (90) | (36) | |||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 36 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (179) | (201) | (421) | (620) | (1,041) | (1,649) | ||
| Other undisclosed income from continuing operations before income taxes | 13 | 61 | 18 | 90 | ||||
| Loss from continuing operations: | (179) | (188) | (360) | (602) | (951) | (1,649) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (602) | (951) | (1,649) | |
| Net loss available to common stockholders, diluted: | (179) | (188) | (360) | (602) | (951) | (1,649) | ||
Comprehensive Income ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (179) | (188) | (360) | (602) | (951) | (1,649) | ||
| Comprehensive loss, net of tax, attributable to parent: | (179) | (188) | (360) | (602) | (951) | (1,649) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.